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INTRODUCTION
Natural killer (NK) and innate lymphoid cells (ILCs) lack highly variable antigen-specific receptors yet express multiple germline-encoded receptors that recognize ligands associated with pathogens (Arase et al., 2002; Li et al., 2013) and cellular stress (Raulet et al., 2013) . Such receptors transmit activating intracellular signals by recruiting the protein tyrosine kinases Syk or ZAP70, either directly or through the adaptors DAP12 and FcRg. These immunoreceptor tyrosine-based activation motif (ITAM) signaling pathways are similar to those induced by antigen-specific receptors (Bezbradica and Medzhitov, 2012) . The human NKp44 receptor (encoded by NCR2) is expressed by activated NK cells (Vitale et al., 1998) , innate lymphoid cells of group 1 (ILC1) (Fuchs et al., 2013) and group 3 (ILC3) (Cella et al., 2009) , and plasmacytoid dendritic cells (Fuchs et al., 2005) , signals through DAP12, and has been implicated in the recognition of transformed cells (Cantoni et al., 1999; Carrega et al., 2015; Sivori et al., 2000; Vitale et al., 1998) . NKp44 has no mouse ortholog. NKp44 ligands have previously been reported (Baychelier et al., 2013; Ho et al., 2008; Rosental et al., 2011; Vieillard et al., 2005) but their physiological relevance in vivo thus far remains elusive.
The platelet-derived growth factor (PDGF) family encompasses four polypeptides that assemble into five dimeric isoforms (PDGF-AA, PDGF-BB, PDGF-AB, PDGF-CC, and PDGF-DD) and engage two receptor tyrosine kinases, PDGFRa and PDGFRb, which are mainly expressed on cells of mesenchymal origin (Andrae et al., 2008) . PDGFR signaling contributes to the embryonal development of multiple organs and blood vessels and promotes wound healing in the adult. Cancer cells frequently produce PDGFs, which trigger autocrine and paracrine PDGFR signaling and promote tumor growth, proliferation, stromal recruitment, angiogenesis, epithelial-mesenchymal transition, and metastasis. A homolog of cellular PDGF encoded by the simian sarcoma virus v-sis oncogene also promotes neoplastic transformation through PDGFR (Deuel et al., 1983) .
By screening a human secretome protein library with an NKp44-GFP reporter cell line, we found that NKp44 recognizes PDGF-DD, which has been shown to stimulate neoplastic transformation and tumor growth through PDGFRb (LaRochelle et al., 2002; Li and Eriksson, 2003; Reigstad et al., 2005; Wu et al., 2013; Xu et al., 2005) . Engagement of NKp44 by PDGF-DD triggered NK cell secretion of interferon gamma (IFN-g), tumor necrosis factor alpha (TNF-a), and other proinflammatory cytokines and chemokines, which in turn induced the downregulation of tumor cell-cycle genes and tumor growth arrest. Meta-analysis of a publicly available database of gene expression profiles for different human cancers revealed a remarkable positive correlation between NCR2 expression, upregulation of PDGF-DDinduced NK cell cytokine genes, and downregulation of tumor 
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Screen N o. cell-cycle genes, along with greater survival in glioblastoma (GBM) . In vivo analysis of NCR2-transgenic mice demonstrated that NKp44 limits the dissemination of PDGF-DD-expressing tumor cells, which was enhanced by checkpoint blockade with anti-CD96 or by CpG-oligonucleotide (ODN) treatment. We conclude that PDGF-DD not only supports tumor growth and stromal expansion through PDGFRb but also facilitates recognition of tumor cells by innate immune cells through NKp44.
PDGF
RESULTS

PDGF-DD Is a Ligand for NKp44
Physiological ligands of NKp44 have remained elusive for almost 20 years. To address this outstanding question, we performed an unbiased screen of a secretome protein library containing $4,000 purified human-and mouse-secreted proteins or ectodomains of single-pass transmembrane proteins for NKp44 ligands (Gonzalez et al., 2010) . To perform the screen, we transfected a chimeric receptor consisting of the human NKp44 extracellular and transmembrane domains fused to the CD3z intracellular signaling domain into a reporter cell line that expresses GFP under the control of NFAT-responsive elements. Ligand engagement of the NKp44-CD3z fusion protein in the reporter cells leads to Ca 2+ mobilization and consequently NFAT transactivation of GFP expression (Arase et al., 2002) . NKp44-GFP reporter cells were seeded into wells coated with individual secretome library proteins and GFP expression detected by flow cytometry (Figure 1A) . The top 30 secreted protein hits from the screen were individually re-tested and among these PDGF-D was validated as a putative NKp44 ligand ( Figure 1B ; Table S1 ). PDGF-D is a member of the PDGF family that signals through PDGFRb (Andrae et al., 2008; Reigstad et al., 2005; Li and Eriksson, 2003) . PDGF-D differs from PDGF-A and PDGF-B in having an unusual N-terminal domain known as complement subcomponent C1r/C1s, Uegf, and Bmp1 (CUB) domain ( Figure 1C ) (Bergsten et al., 2001) . PDGF-D is secreted as a dimer and must undergo extracellular proteolytic processing of the CUB domain by proteases, such as urokinase plasminogen activator and matriptase (Bergsten et al., 2001; Huang and Kim, 2015; Ustach and Kim, 2005; Ustach et al., 2010) , to liberate active homodimeric PDGF-DD that binds to and activates PDGFRb signaling ( Figure 1C ).
NKp44-GFP reporter cells expressed GFP when cultured in serum-containing medium with either recombinant PDGF-D ( Figure 1D ) or the processed PDGF-DD form ( Figure 1E ). Corroborating the specificity of these interactions, a monoclonal antibody (mAb) against PDGF-D blocked NKp44-GFP reporter activation by PDGF-D and PDGF-DD ( Figures 1D and 1E ). However, a chimeric protein consisting of the NKp44 ectodomain fused to the Fc domain of human IgG (NKp44-Fc) specifically bound to PDGF-DD but not to PDGF-D by solid phase binding assay, demonstrating that NKp44 effectively binds to active PDGF-DD ( Figure 1F ). PDGF-D most likely activates NKp44-GFP reporter cells because it is processed by serum proteases contained in the culture medium. PDGF-DD-induced activation of NKp44-GFP reporter cells was dose-dependent and saturated at high PDGF-DD concentrations ( Figure 1G ). Biacore analysis determined that PDGF-DD has a 3.3 ± 0.4 mM affinity for the Ig superfamily (IgSF) domain of NKp44 ( Figure 1H ), within the known range of the PDGF/PDGFR interactions (Shim et al., 2010) , and confirmed that NKp44 does not bind to unprocessed PDGF-D ( Figure 1I ). NKp44 ligands (NKp44L) have been proposed, such as viral hemagglutinins (Ho et al., 2008) , and the nuclear proteins proliferating cell nuclear antigen (PCNA) (Rosental et al., 2011) and mixed-lineage leukemia protein 5 (MLL5) (Baychelier et al., 2013; Vieillard et al., 2005) . We did not detect NKp44 interaction with either EL4 cells overexpressing PCNA ( Figures S1A-S1C ), or CHO cells transfected with three different influenza virus hemagglutinins (Figures S1D and S1E) using NKp44-Fc binding and/or activation of NKp44-GFP reporter cells. Similarly, no interaction of NKp44 was detected with human CD4 + T cells stimulated with an HIV gp41-derived peptide, which purportedly induces cell-surface expression of MLL5 (Figures S1F and S1G), or with Jurkat T cells that were reported to express cell-surface MLL5 ( Figure S1H ) (Baychelier et al., 2013) . Potential low-affinity interactions of NKp44 with these putative ligands and their physiological relevance remain unclear. Altogether, these results show that the proteolytically processed ''active'' PDGF-DD growth factor is a bona fide ligand for NKp44.
PDGF-DD Triggers NK Cell Activation and Cytokine Secretion via NKp44
We first investigated whether PDGF-DD evokes ITAM signaling in human NK cells. The human NK cell line NK92 expresses NKp44. PDGF-DD induced Ca 2+ mobilization in NK92, which was blocked by anti-NKp44 ( Figure 2A ). Furthermore, PDGF-DD induced phosphorylation of AKT, ERK, and its downstream target FOXO3A in primary human NK cells ( Figure 2B ). Because activated human NK cells express the NKp44/DAP12 receptor complex, but not PDGFRa or PDGFRb ( Figure S2A ), we conclude that PDGF-DD binding to NKp44 triggers ITAM signaling in human NK cells. We next determined the impact of PDGF-DD-NKp44 interactions on NK cell functions. Incubation of IL-2-activated NKp44 + NK cells from normal donors with increasing concentrations of PDGF-DD induced dose-dependent cell surface expression of CD107a ( Figure S2B ), which is indicative of cytokine secretion and/or the release of lytic granules. Induction of CD107a expression was blocked by anti-NKp44 ( Figure S2C ), corroborating that PDGF-DD acted via NKp44 and not through other receptors. Similar induction of CD107a was observed when NK cells were stimulated with an NKp44 surrogate ligand (i.e., anti-NKp44 antibody crosslinked with a secondary antibody) ( Figure S2C CD107a, forced expression of PDGF-DD in target cell lines normally resistant to NK cell killing was insufficient to elicit NK cell cytotoxicity and only modestly enhanced antibody-dependent cellular cytotoxicity, which relies on activation of FcgRIII (CD16) on NK cells by an antibody bound to target cells (data not shown). These results are consistent with previous studies showing that NKp44 promotes target cell lysis only in combination with other activating receptors (Sivori et al., 2000; Vitale et al., 1998) .
In contrast, PDGF-DD alone was sufficient to induce robust and dose-dependent IFN-g and TNF-a secretion by interleukin (IL)-2-activated NKp44 + NK cells ( Figures 2C and 2D ), which was blocked by anti-NKp44 ( Figures 2E and 2F ), further supporting specific PDGF-DD/NKp44 interaction. Induction of IFN-g and TNF-a was also obtained by stimulating NK cells using antibodymediated cross-linking of NKp44 as surrogate ligand (Figures 2E and 2F) . PDGF-DD stimulated the secretion of IFN-g and TNF-a from NK cells derived from normal donors but not from an individual carrying a homozygous deletion of the TYROBP gene that encodes for DAP12 (Figures 2E and 2F) . These DAP12-deficient NK cells lack cell surface expression of NKp44 as well as all DAP12-associated receptors (Fuchs et al., 2005) . Intracellular staining for IFN-g and TNF-a revealed that PDGF-DD stimulation of normal NK cells, but not DAP12-deficient NK cells, induced IFN-g-producing cells as well as bifunctional cells secreting both IFN-g and TNF-a ( Figure 2G ). Cell surface staining for NKp44 of PDGF-DD-stimulated NK cells showed downregulation of NKp44 ( Figure 2H ), probably reflecting ligand-induced internalization of this receptor. To provide further evidence that active PDGF-DD induces NK cell cytokine secretion, we engineered a construct encoding a full-length PDGF-D protein with a tobacco etch virus (TEV) protease cleavage site (CUB-TEV-PDGFD) in front of the growth factor domain. Incubation of CUB-TEV-PDGFD with TEV protease released active PDGF-DD ( Figure S2D ), which effectively induced NK cell secretion of IFN-g and TNF-a ( Figures S2E and S2F ). CUB-TEV-PDGFD was in part active, probably because CUB-TEV-PDGFD is cleaved into PDGF-DD by serum proteases during the time required to perform the assay. We asked how PDGF-DD impacts global gene expression in NK cells by RNA sequencing (RNA-seq) of unstimulated and PDGF-DD stimulated NK cells from four different donors. Collectively, induction of 1,384 unique transcripts and downregulation of 721 transcripts was evident in the transcriptional profiles of PDGF-DD-activated NK cells compared to unstimulated NK cells ( Figure 2I ). Induced genes encoded IFN-g, TNF-a, and other proinflammatory cytokines including LTa and GM-CSF, as well as chemokines, such as CCL3, CCL4, CCL4L2, XCL1, and XCL2 ( Figure 2I ). Transcripts encoding cell surface markers of activation, such as TNFSF4 and TNFRSF9 (CD134L and CD137), and transcription factors involved in ITAM signaling, cellular activation, and proliferation, such as IRF4, EGRs, and EOMES, were also upregulated ( Figure 2I ). Downregulated genes encoded components of the ITAM signaling pathways, suggesting a feedback mechanism in which the functional activation of ITAM signaling mediators is paralleled by their reduced transcription. Ingenuity pathway analysis (IPA) of PDGF-DDinduced transcriptional changes corroborated the induction of pathways involved in NK cell and T cell activation, proliferation, and survival as well as IFN-g signaling ( Figure 2J ). Thus, PDGF-DD binding and signaling through the NKp44/DAP12 receptor complex leads to pronounced NK cell activation characterized by secretion of proinflammatory cytokines and chemokines.
PDGF-DD Triggers Cytokine Secretion in ILC3 and ILC1
We sought to test whether PDGF-DD also activated human ILC3 and intraepithelial ILC1, because these cells were initially revealed through their distinctive expression of NKp44 in mucosal tissues (Cella et al., 2009; Fuchs et al., 2013) and have been implicated in cancer immunosurveillance (Carrega et al., 2015; Dadi et al., 2016) . Although NKp44 + ILC3 isolated from tonsil can produce IL-22, GM-CSF, and TNF-a, PDGF-DD selectively induced TNF-a ( Figures 3A, 3B , and S3). IL-23 induced IL-22, as reported (Cella et al., 2009) , while concurrent PDGF-DD and IL-23 stimulation did not further increase TNF-a or IL-22 production (Figures 3A, 3B, and S3) . This result corroborates the observation that stimulation of NKp44 in ILC3 with a specific mAb as a surrogate ligand selectively induces TNF-a (Glatzer et al., 2013) . We also determined the impact of PDGF-DD on ILC3 cultured in vitro with IL-1b and IL-2, a condition that converts ILC3 into (A) PDGF-DD induces calcium signaling in NK92 cells, which is blocked by anti-NKp44 mAb. (B) IL-2 cultured NK cells were stimulated with PDGF-DD for the indicated time points and phosphorylated AKT, ERK1/2, and FOXO3A and total ERK1/2 determined by immunoblotting. (C and D) PDGF-DD stimulates dose-dependent NK cell secretion of IFN-g (C) and TNF-a (D). NK cells were kept in IL-2 medium throughout the assay. (E and F) IFN-g (E) and TNF-a (F) secretion by PDGF-DD-stimulated NK cells derived from either normal donor (Norm) or DAP12-deficient (D12) patient. Induction of IFN-g and TNF-a is blocked by anti-NKp44 (E and F) . In the absence of PDGF-DD, IFN-g and TNF-a can be induced by cross-linking NKp44 with Ga M+a-NKp44 as surrogate NKp44 ligand (E and F) . (G) Representative dotplots of intracellular IFN-g and TNF-a staining of PDGF-DD-stimulated IL-2-cultured NK cells from normal (Norm) or DAP12-deficient (D12) donors (percentage expression indicated in each quadrant). PMA/i was used as positive control. (H) Representative histograms of NKp44 surface expression on IL-2-cultured NK cells from normal (Norm) or DAP12-deficient (D12) donors before and after PDGF-DD stimulation. (I) Volcano plot and heatmap analysis of RNA-seq transcriptional profile induced by PDGF-DD in 4 NK cell donors. Transcripts in red were upregulated at least 1.5-fold by PDGF-DD (NK;1-4_PD) versus unstimulated NK cells (NK;1-4), those in blue were similarly downregulated. (J) Top 10 highest scoring IPA cellular immune response pathways generated from transcripts differentially expressed (± 1.5-fold) in PDGF-DD-stimulated NK cells as in (I). Ratios in columns indicate total PDGF-DD-regulated genes to the total number of genes in each pathway. Error bar represents mean ± SEM (****p % 0.0001). See also Figure S2 . IFN-g-producing ILC1-like cells (Cella et al., 2010) . PDGF-DD promoted secretion of both IFN-g ( Figure 3C ) and TNF-a (Figure 3D ) in a dose-dependent fashion that was blocked by antiNKp44, but not a control antibody. We finally tested the impact of PDGF-DD on the transcriptome of tonsilar intraepithelial ILC1 expanded in vitro with IL-2. In comparison to unstimulated ILC1, PDGF-DD induced the expression of 127 genes and downregulation of 102 genes ( Figure 3E ). PDGF-DD-induced genes were similar to those induced in NK cells, including IFNG, CCL1, CCL3, CCL4, and IRF4 ( Figure 3E ). IPA of PDGF-DD-induced changes in ILC1 gene expression profiles confirmed the involvement of lymphocyte activation and IFN-g signaling pathways ( Figure 3F ). We conclude that PDGF-DD induces an NKp44-dependent proinflammatory gene program in ILC3, converted ILC3, and intraepithelial ILC1. Figure 4I ). IL8 and CD155 were also upregulated. Transcripts that were downregulated in comparison to unstimulated cells (1, 192) included many cell-cycle genes ( Figure 4I ). IPA analysis confirmed that treatment of cancer cells with TC supernatants from PDGF-DD-activated NK cells induced pathways involving IFN-g signaling, antigen presentation, and cell-cycle control of chromosomal replication ( Figure S4 ). Altogether, these data show that tumor cells exposed to PDGF-DD-induced NK cell-secreted cytokines undergo cell-cycle arrest but also express inflammatory cytokines, chemokines, and cell-surface ligands that can broadly influence the immune response to tumors. Figures S5J-S5X ). PDGF-D was expressed in GBM ( Figure 5A ) and was highly associated with vascular proliferation ( Figure 5B ). Thus, PDGF-D is expressed in cancer cells and/or stroma of many human tumors with aggressive features. We next defined a core expression signature for the 9 most highly induced cytokine genes in PDGF-DD-activated NK cells from different donors ( Figure 5C ) and a core signature of 34 most significantly downregulated cell-cycle genes in human ovarian carcinoma, breast carcinoma, and melanoma cell lines exposed to NKp44
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DD+IgG sup ( Figure 5D ). We interrogated The
Cancer Genome Genome Atlas (TCGA; https://cancergenome. nih.gov/), a comprehensive map of the transcriptional changes in multiple types of cancer, for correlations between NCR2 expression and the cytokine gene signature in various human cancers. Remarkable correlations were found in the TCGA GBM cohort (539 patients); NCR2 expression positively correlated with 6 of 7 available core cytokines extracted from the GBM TCGA cohort ( Figure 5E ). The canonical correlation of NCR2 with the cytokine variate was 0.60 (Table S2 ).
The correlation between NCR2 expression and the NK cell cytokine gene signature in GBM suggested that NKp44 + NK cells might infiltrate GBM. Indeed, we observed numerous NKp44 + cells along with relatively few T cells infiltrating GBM in tissue sections obtained from several patients ( Figure 5F ); however, a GBM variant known as gliosarcoma was infiltrated by more T cells and fewer NKp44 + cells, which suggests that lymphocytic infiltrates of GBM vary somewhat. Further supporting NK cell infiltration in GBM, NCR2 expression in the GBM TCGA cohort was positively correlated with expression of the NK cell-specific gene NCR3, which encodes the activating receptor NKp30 ( Figure 5G ). These results indicate that infiltration of NKp44 + NK cells is present in many, but not all, GBM and positively correlates with the expression of proinflammatory NK cell cytokine genes such as IFNG and TNF. We next determined the correlation between NCR2 and the expression of the tumor cell-cycle gene signature (see Figure 5D ) for GBM. Strikingly, NCR2 expression negatively correlated with the expression of 25 of 27 available core cell-cycle genes in the GBM TCGA cohort ( Figure 5H ). The canonical correlation of NCR2 with the cell-cycle variate was 0.68 (Table S3) . We next examined if NCR2 expression was correlated with greater overall survival in the GBM cohort. GBM patients in the upper quartile (Q4) expression of the canonical cytokine ( Figure 5I ) and cell-cycle ( Figure 5J ) variates of NCR2 had greater overall survival compared to GBM patients in the lower quartile (Q1) (p = 0.0266 and p 0.0093, respectively). We also observed a trend toward increased survival from the 1 st to the 4 th quartile of NCR2 expression but it was not statistically significant, probably because the dynamic range of NCR2 expression in TCGA GBM mRNA was limited (data not shown). Thus, meta-analysis of TCGA database indicates that overall survival correlates not only on the expression of NCR2 but also on the downstream effects of NKp44 engagement by PDGF-DD. While other types of tumors also showed associations of NCR2 expression with NK cell core cytokine signature, and/or downregulation of tumor cell-cycle genes, correlations with overall survival were not significant (data not shown), suggesting that the contribution of PDGF-DD/NKp44 interaction to control of tumor progression may be context-dependent.
(D) Colo38 cells were cultured in either complete medium or NK DD+IgG sup with (+) or without anti-IFN-g and anti-TNF-a (Abs) before washing and passaging in complete medium as described above.
(E-G) Cells were pre-cultured in either NK DD+IgG sup, NK DD+a-NKp44 sup, or complete medium, washed, then re-plated in complete medium and the secretion of IL-8 for Colo38 (E) and Meljuso (F) or the secretion of IL-6 for Colo38 (G) measured in the culture medium at the end of the first passage.
(H) Representative dotplots of CADM1 (assessed by CRTAM-Fc binding), CD112, CD155, and CD95 (Fas) expression from Colo38 cells exposed to NK DD+IgG sup or NK DD+a-NKp44 sups (24 hr).
(I) RNA-seq profiles of human melanoma (Colo38 and Meljuso), breast cancer (MCF7) and ovarian cancer (OVCA) cell lines exposed to either NK DD+IgG sup or NK DD+a-NKp44 sup (48 hr). Transcripts in red were upregulated at least 1.5-fold and those in blue were similarly downregulated.
Error bar represents mean ± SEM. ***p % 0.001; ****p % 0.0001; ns, not significant. See also Figure S4 .
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PDGF-DD Binding to NKp44 Limits Tumor Growth In Vivo
Because NKp44 is encoded only in humans, we developed bacterial artificial chromosome (BAC) NCR2 transgenic (tg) mice to determine the impact of PDGF-DD/NKp44 interactions on cancer in vivo. Two NCR2-tg lines were generated; in both, expression of the NKp44 transgene mirrored NKp44 expression in the human immune system, although NKp44 was expressed at slightly higher levels in one line. In steady state, NKp44 was found on a small subset of splenic and lymph node NK cells (Figures 6A, S6A, and S6B). NKp44 was also expressed on a larger subset of ILC3 and few NK/ILC1 cells in the small intestine ( Figures  S6C and S6D ). Upon in vitro activation with IL-2 and IL-15, NK cells showed a marked upregulation of NKp44, which was increased by further stimulation with inflammatory cytokines (Figure 6B) . To determine the impact of PDGF-DD/NKp44 interaction on anti-tumor NK cell activity in vivo, we chose the B16 metastatic tumor model, which has been shown to be sensitive to NK cells, particularly to their IFN-g secretion capacity (Takeda et al., 2011) . We generated B16F10 melanoma cells stably expressing either a bicistronic gene encoding human PDGFD and GFP (B16-PDGFD) or the backbone vector (B16-pMX) as control cells ( Figure 6C ). Incubation of TC supernatants from B16-PDGFD cells (B16-PDGFD sup) with human NK cells promoted the secretion of IFN-g and TNF-a, which was dependent on NKp44 and PDGF-DD ( Figures 6D and 6E ), whereas control TC supernatants from B16-pMX cells did not activate NK cells unless recombinant PDGF-DD was added to the cultures ( Figures S6E and S6F ). Two weeks after intravenous injection of B16-PDGFD cells, NCR2-tg mice had fewer surface metastases (Figures 6F and S6G) , diminished mean tumor area (Figures 6G and S6H) , as well as augmented expression of Ifng ( Figure 6H ), but not Tnf (Figure 6I) , in lungs compared to non-tg littermates. B16-PDGFD cells formed more lung metastases in NCR2-tg mice treated with blocking anti-NKp44 compared to a control mAb ( Figure 6J ), corroborating that higher rejection of B16-PDGFD cells in NCR2-tg mice depends on NKp44. Moreover, lung surface metastases formed by B16-pMX control cells did not differ between NCR2-tg and non-tg littermate mice, indicating that NCR2-tg mice had no inherent advantage over non-tg mice in restricting B16F10 cells ( Figure 6K ). We conclude that PDGF-DD/NKp44 interactions facilitate NK cell control of tumor expansion in vivo.
NKp44-PDGF-DD Interaction Enhances Checkpoint Blockade
We sought to determine whether the NKp44-PDGF-DD interaction would synergize with checkpoint blockade in tumor rejection. We first examined NK cell expression of NKp44 along with the inhibitory checkpoint receptors PD-1 (Kline and Gajewski, 2010), TIGIT (Blake et al., 2016) , and CD96 (Blake et al., 2016) in the lungs and lymph nodes of NCR2-tg mice. In tumor-free NCR2-tg mice, NK cells did not express NKp44, CD96, PD1, or TIGIT ( Figure 7A ; data not shown). In contrast, NKp44 and CD96, but not PD-1 or TIGIT, were expressed on NK cells in the lungs and lymph nodes of NCR2-tg mice that had been intravenously injected with B16-PDGFD cells (Figures 7B and 7C) . Moreover, the CD96 ligand, CD155, was induced on B16F10 cells by IFN-g and TNF-a ( Figure 7D ). Thus, we hypothesized that blockade of the CD96-CD155 interaction might augment NK cell activation and limit B16-PDGFD cell metastases (Blake et al., 2016) . Indeed, anti-CD96 treatment lowered the number of B16-PDGFD surface lung metastases formed in NCR2-tg and non-tg littermates. Importantly, B16-PDGFD surface lung metastases were fewer in NCR2-tg mice compared to non-tg mice receiving anti-CD96 immunotherapy ( Figure 7E ). Thus, PDGF-DD/NKp44 interaction and anti-CD96 immunotherapy cooperate in NK cell control of B16-PDGFD cell metastases.
NKp44 Engagement Boosts CpG-Induced Control of Subcutaneous Melanoma
In contrast to the lung B16 metastatic model, NK cells have little impact on subcutaneous B16 melanoma, probably due a poorly immunogenic environment that prevents NK cell activation. However, it has been shown that CpG-ODN immunotherapy can stimulate NK cell recruitment, activation, and NK cell-dependent regression of subcutaneous B16 melanoma (Liu et al., 2008) . We examined whether the NKp44-PDGF-DD axis can impact the ability of CpG-ODN to restrict the growth of subcutaneous melanoma. In the absence of CpG treatment, tumor growth of subcutaneous B16-PDGFD melanoma was equally unrestricted in NCR2-tg or non-tg littermates ( Figure 7F ). Conversely, in mice receiving CpG-ODN, growth of B16-PDGFD tumors was restricted sooner in NCR2-tg compared See also Figure S5 and Tables S2 and S3. to non-tg littermates ( Figure 7F ). (Groh et al., 2002) . Sustained production of IFN-g may also be co-opted in the tumor environment (Nirschl et al., 2017) . Finally, it is possible that the PDGF-DD/NKp44 contribution is obscured by other concurrent innate and/or adaptive immune responses (Gajewski et al., 2013) . Overall, the impact of PDGF-DD/NKp44 interactions may be more complex than just the control of cell growth observed in our experimental settings and may have diverse effects on tumor editing and progression in different contexts.
NCR2-tg
PDGF-DD contributes to angiogenesis, embryonal development of various organs, formation of the placenta during pregnancy, and supports wound healing (Li and Eriksson, 2003; Reigstad et al., 2005) . In disease, PDGF-DD has been implicated in vascular diseases (Chen et al., 2005) , mesangioproliferative glomerulonephritis, and fibrosis (Reigstad et al., 2005) . Polymorphisms in PDGFD have even been associated with coronary artery disease (Nikpay et al., 2015) and serum levels of IFN-g (Ahola-Olli et al., 2017) . Thus, PDGF-DD/ NKp44 interactions may play wider biological roles beyond cancer.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Mice
Mice were of mixed sexes. Mice within experiments were age and sex matched. All mice were between 8-12 weeks of age at the time of use. Mice used in this study were NCR2-tg and non-tg littermate mice. Mice were housed under specific pathogen free conditions. Mice did not undergo any procedures prior to their stated use. Sex matched littermate mice were randomly assigned to experimental groups for anti-CD96 and CpG 2216 DNA treatments. All studies performed on mice were done in accordance with the Institutional Animal Care and Use Committee at Washington University in St. Louis, which approved all protocols used in this study.
Human tissues and primary cells
All human tissues and cells (normal and cancer) used in this study were obtained under the approval of the institutional review boards of Washington University in St Louis and the University of Brescia, respectively. Informed consent was obtained from all patients for the use of all human tissue and cells used in this study. Tonsils were obtained from children undergoing elective tonsillectomy (Children's Hospital, Washington University School of Medicine). Peripheral blood products were obtained from the pheresis unit of the Washington University School of Medicine Center of Advanced Medicine. Tonsilar lymphocyte suspensions and peripheral blood mononuclear cells (PBMC) were prepared as previously described (Cella et al., 2009 (Cella et al., , 2010 . Briefly, CD56 + cells were enriched from PBMC and tonsil lymphocytes by magnetic cell sorting using CD56 MicroBeads (Miltenyi Biotec). NK cells and ILC subsets were sorted from CD56 + cells, as previously reported (Cella et al., 2010) . Human CD4 + T cells were enriched from PBMC by magnetic cell sorting using CD4 MicroBeads (Miltenyi Biotec). Mouse lamina propria leukocytes were prepared as previously described (Lefranç ois and Lycke, 2001). Formalin-fixed paraffin-embedded (FFPE) human tissues used for this study were retrieved from the archive of the Department of Pathology (ASST Spedali Civili di Brescia, University of Brescia, Brescia Italy) and included reactive lymphoid organs (tonsils and lymph nodes) and normal non-lymphoid tissue (colon, stomach, thyroid, salivary gland, breast, lung, liver, pancreas, skin, kidney, bladder, testis, prostate) . PDGF-D analysis was also screened on a set of seventy-five human neoplasms (FFPRE blocks) including primary (13 cases) and metastatic (22 cases) melanoma, glioblastomas (5 cases), gastrointestinal stromal tumor (4 cases) and a set of carcinomas from different sites including lung (5 cases), ovary (2 cases), breast (2 cases), bladder (2 cases), colon (5 cases), prostate (6 cases), stomach (2 cases), kidney (5 cases), head and neck (2 cases). NKp44 staining was performed on frozen material from 10 cases of glioblastoma (6 cases, University of Brescia; four, Washington University in St. Louis), which included one case of gliosarcoma GBM variant (Washington University in St. Louis).
Cell lines
NKp30-and NKp44-GFP reporter cells were maintained in 10% FBS in RPMI 1640 supplemented with sodium pyruvate, GlutaMAX, and penicillin/streptomycin. NKp30-and NKp44-GFP reporter cells were based on the 2B4 NFAT-GFP cells developed by Arase et al. (Arase et al., 2002) . The sex of the mouse from which the 2B4 T cell hybridoma was derived has not been reported (Arase et al., 2002; Hedrick et al., 1982) . Colo38 is a human female malignant melanoma cell line (Chang et al., 2005) . Meljuso is a human female cutaneous melanoma cell line (Deschodt-Lanckman et al., 1990) . OVCA is a human female ovarian serous adenocarcinoma cell line (Bast et al., 1981) . MCF7 is a human female breast carcinoma cell line (Soule et al., 1973) . NK92 is a human male NK cell lymphoblastic leukemia/lymphoma cell line (Gong et al., 1994) . Jurkat is a human male T lymphoblastic leukemic line (Schneider et al., 1977) . B16F10 is a male mouse melanoma cell-line (Nakamura et al., 2002) . J558L is a mouse plasma cell myeloma cell line. The sex of the mouse from which the J558L myeloma cell line was derived has not been reported (Oi et al., 1983) . EL4 is a mouse thymic lymphoma cell-line (Gorer, 1950) . The sex of the mouse from which the EL4 cell line was derived has not been reported. The Phoenix amphotropic packaging cell-line and HEK293F are derivatives of the human female embryonic kidney (HEK) 293 cell-line (Lin et al., 2014) . CHO is a female Chinese hamster ovary cell-line.
METHOD DETAILS
Preparation of NCR2 transgenic mice The RP11-380E17 BAC ($300 kb) was chosen because it encoded the complete human NCR2 gene on chromosome 6p21.1 in addition to sufficient upstream ($142kb) and downstream ($142kb) sequence to include all the necessary elements required for correct expression of NKp44. The RP11-380E17 BAC clone was purchased from Invitrogen, isolated and purified using the QIAGEN Maxiprep kit. PCR using the following primers located in genomic regions covering NCR2:
, and 5 kb downstream (Forward, 5 0 -GGCTAAGAGGGGCCATCACG-3 0 ; Reverse, 5 0 -AGGATACAGGGGCAGGTGTTG-3 0 ), served to screen for positive BAC clones containing the complete NCR2 gene ready for pronuclear injection. Purified BAC DNA was then used to generate BAC transgenic mice on a CBA/C57BL/6J background in the Washington University School of Medicine Mouse Transgenic and Gene Targeting Core Facility using standard transgenic methods. PCR on tail-snip DNA using human-specific primers corresponding to an internal site on the transgene (Forward, 5 0 -ATCATTCTCCAGGCTCTCAGGCACAATCCA-3 0 ; Reverse, 5 0 -CATGGTGACAGTGAAGAAGCCAGCATCAGG-3 0 ) confirmed that the BAC had fully integrated. We used 2 transgenic founders to establish 2 independent transgenic lines for further characterization. We then crossed each of these lines further onto the C57BL/6J background to obtain mice homozygous for Klrb1 (encoding the NK1.1 antigen) at the C57BL/6J Natural Killer Receptor (NKR) locus. Mice were maintained on a standard 12 hour light/dark cycle with food and water available ad libitum. All procedures were conducted in strict accordance with the NIH Guide for the Care and Use of Laboratory Animals and all studies performed on mice were approved by the Washington University in St. Louis Institutional Animal Care and Use Committee.
Screening of the GNF secretomics library
A cell line with GFP reporter readout driven by NFAT-responsive promoter elements that stably expresses an integrated construct encoding a fusion protein of the NKp44 extracellular and transmembrane domains with the intracellular cytoplasmic tail of CD3z (NKp44-GFP reporter cells) was generated for screening a library of secreted proteins (Gonzalez et al., 2010) for NKp44 ligands. Engagement of the chimeric NKp44-CD3z receptor results in GFP expression. GFP reporter cells expressing a fusion protein consisting of the NKp30 extracellular and transmembrane domains with the intracellular cytoplasmic tail of CD3z (NKp30-GFP reporter cells) were also generated. Library proteins were coated onto a 384-well tissue culture (TC) treated plate in duplicate at 5-fold dilution from a stock in a final volume of 25 mL/well. Stock solutions varied in concentration ranging from $0.1 to $50 mM. The proteins were allowed to adsorb overnight at 4 C. The following day, protein coated plates were washed with 80 mL of PBS and NKp44 or NKp30 reporter cells, previously cultured to 70% confluence in T175 flasks, were seeded into protein coated plates at a density of 35,000 cells per well in 50 mL volume of culture medium. After 24 hours incubation at 37 C, 5 mL/well of a 2 mg/mL DAPI dilution was added to each well for detection of dead cells, bringing the final volume/well to 55 mL. Flow cytometry was used to acquire GFP and DAPI signal from each well. Candidate proteins were retested in the same 384 well format using serial dilutions from library stocks as indicated. The GNF Secretomics library (Gonzalez et al., 2010) screened contains purified versions of known and predicted mouse and human secreted proteins as well as extracellular domains of single pass transmembrane proteins. Anti-NKp44 and anti-NKp30 were immobilized to plates using goat anti-mouse Ig and used as positive and negative controls, respectively. Results of initial screen are expressed as normalized fluorescence signal (NFS).
Immobilization of antibodies, proteins and peptides 2% BSA, or 5 mg/mL of proteins or antibodies were immobilized in 100 mL PBS onto TC or ELISA plates, as previously described (Barrow et al., 2011) . Briefly, all wells were washed 3 times in Tris buffered saline (10 mM Tris-HCl pH 7.5, 150 mM NaCl) + 0.05% Tween-20 (TBS-T) to remove excess proteins before blocking in 5% BSA in TBS-T for 1 hour at 37 C prior to performing binding assays.
Solid-phase binding assay
Solid-phase binding assays were performed as previously described (Barrow et al., 2015) . After blocking, NKp44-Fc fusion protein was diluted in 100 mL of TBS-T + 0.1% BSA and incubated for 1 hour at room temperature (RT) in ELISA plate wells coated with the different proteins. Wells were then washed five times in TBS-T before incubating with 100 mL 1:5000 HRP-conjugated goat anti-human Ig (Southern Biotech) in 100 mL of TBS-T for 1 hour at RT. Wells were then washed a further five times in TBS-T before developing with O-Phenylenediamine dihydrochloride and the absorbance at 492 nM recorded using a plate reader. BSA, recombinant Chikungunya virus (CHIK) E2 protein and IL-17A were used as negative controls. Recombinant CUB-TEV-PDGFD contains a TEV cleavage site between CUB and GFD.
Calcium imaging using flexstation III NK92 cells were loaded with 1 mM Fura-2 AM in Ringer's buffer (135 mM NaCl, 5 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 5.6 mM Glucose, and 10 mM HEPES, pH 7.4) for 40 min in the dark, washed, and then plated in 96-well plates at a density of 10 5 cells/well with primary antibodies. Fura-2 excitation ratios were measured by alternatively exciting the dye at 340 and 380 nm, at a frequency of $1 image pair every 4 s and collecting emission at 510 nm using Flexstation III (Molecular Devices) equipped with SoftMax Pro 5 software (Molecular Devices). Recombinant PDGF-DD was injected after 180 s to a final concentration of 1 mg/mL.
Immunoblotting IL-2 cultured NK cells were serum-starved in RPMI 1640 medium for two hours at 37 C prior to stimulation with 250 ng/mL PDGF-DD for the indicated time points. Following PDGF-DD stimulation, NK cells were placed on ice, washed once in ice cold PBS before resuspending in ice cold lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% Triton X-100) containing 1 mM PMSF, 1 mM Na 3 VO 4 , leupeptin and apoprotinin (1 mg/mL each), and 1x phosphatase inhibitor cocktail 3 (Sigma Aldrich Cat. Number P0044) on ice for 10 mins. After centrifugation at 13,000 rpm for 15 mins at 4 C to pellet cellular debris, sample supernatants were removed and 4x SDS-PAGE loading buffer (200 mM Tris-HCl pH 6.8, 8% sodium dodecyl sulfate, 0.4% bromophenol blue, 40% glycerol and 400 mM dithiothreitol) added. Lysates were heated to 95 C for 10 minutes and run on a 4%-12% bis-tris gel (Nupage). Proteins were transferred to nitrocellulose and blocked for 1 hour at RT in 5% BSA in TBS-T. Membranes were incubated in primary antibody overnight at 4 C. Membranes were subsequently washed and incubated in Goat anti-rabbit HRP (Southern Biotech) for 1 hour at RT, washed, and developed using SuperSignal West Pico Chemiluminescent Substrate.
Plasmids
Human PDGFD (residues E184-R370) and NKp44 (residues G18-S130 including a C-terminal His6 tag) were cloned into the NdeI and NotI restriction sites of the pET21 bacterial expression vector. Full-length PDGFD (residues 1-370), with or without an internal Tobacco Etch Virus (TEV) protease recognition sequence (ENLYFQS) preceding the cytokine domain (R254), a C-terminal TEV protease site and His6 tag, was cloned downstream of the CMV promoter in the IRES-RFP mammalian expression vector pFM-1.2. The NKp44 ectodomain and transmembrane region was cloned in frame with human CD3z into the pEF6/V5-His mammalian expression vector. The NKp44 extracellular domain was cloned into the pHuIgG1 vector to make the resulting NKp44-Fc vector containing the exons for the hinge, CH2 and CH3 regions of human IgG1, the guanosine phosphotransferase gene conferring resistance to mycophenolic acid, and the k promoter for expression in mouse myeloma, as described before (Boles et al., 2005) . Cloning of the CRTAM-Fc fusion protein to detect expression of Necl-2, has been described before (Boles et al., 2005) . Full-length human PDGFD or PCNA were cloned into the EcoRI and NotI sites of the pMX-IRES-eGFP retroviral expression vector, respectively.
Generation of stable cell-lines GFP reporter cells were generated by electroporation of the NKp44-CD3z fusion construct or NKp30-CD3z fusion constructs, respectively, and selection of stable clones with Blasticidin. J558L myeloma cells were electroporated with NKp44-Fc vector and secreting transfectants selected in mycophenolic acid xanthine (Sigma-Aldrich). For the generation of stable B16F10 and EL4 cells, the Phoenix amphotropic retroviral packaging cell-line was transfected with either pMX-IRES-eGFP or pMX-IRES-eGFP (Kitamura et al., 2003) encoding either PDGFD or PCNA, respectively. Cells were infected with the resulting amphotropic retroviruses and single-cell clones stably expressing similar levels of GFP selected in the presence of puromycin.
Recombinant Proteins
Human PDGFD (E184-R370) and NKp44 (G18-S130) were expressed in BL21 (DE3) codon plus E. coli cells by autoinduction (Studier, 2005) . The proteins were refolded from inclusion bodies denatured in 7 M guanidinium hydrochloride, 30 mM b-mercaptoethanol centrifuged for 10 min at 4 C and diluted to 2 M guanidinium hydrochloride in 50 mM sodium acetate pH 5.2. The supernatant was filtered and refolded by rapid, serial dilution (1 mL injections, hourly) in 1 liter of refolding buffer (400 mM L-arginine, 100 mM Tris-base pH 8.3, 2 mM EDTA, 0.5 mM oxidized glutathione, 5 mM reduced glutathione, and 0.2 mM phenylmethanesulfonyl fluoride) at 4 C. The recombinant proteins were concentrated using a stirred cell concentrator with YM10 membrane (Millipore), centrifuged to remove aggregates and purified on an S-75 size exclusion chromatography column equilibrated in 20 mM HEPES pH 7.4 and 150 mM NaCl, 0.01% sodium azide. Full-length PDGFD and TEV cleavable PDGFD proteins were transiently expressed in serum-free HEK293F suspension cells and purified by Ni-NTA agarose affinity (QIAGEN) and Superdex 200 gel filtration chromatography, cleaved where appropriate by the addition of TEV protease, and samples at 0 and 24 hours were analyzed by SDS-PAGE. Recombinant PDGF-DD used for in vitro cell stimulations was purchased from R&D systems. NKp44-Fc fusion protein was purified from J558L TC supernatants, as previously described.
Surface plasmon resonance Affinity analysis was performed using SPR (BIAcore T100, GE Company) at 25 C in 10 mM HEPES, 150 mM NaCl, 3 mM EDTA and 0.05% v/v surfactant P20. PDGFD, PDGF-DD or a control protein (IL17A or Chikungunya E2 glycoprotein) was immobilized (500-1000 Response Units) onto a CM5 chip (GE healthcare) using amine-coupling chemistry. Bacterial expressed NKp44 (residues 18-130 with a C-terminal His6 tag) was injected at a flow rate of 20 mL/min at concentrations ranging from 0.036 mM to 36.8 mM for 5 minutes to saturate binding and then allowed to dissociate for 20 minutes. Under these conditions, regeneration of the chip surface was not necessary. The observed binding curves were double referenced to a control protein (human IL-17A or Chikungunya E2 glycoprotein) as well as buffer in the absence of NKp44. Curves were analyzed by a steady-state fit for a 1:1 interaction, and a nonlinear least-squares fit was used to evaluate the fit of the curve to the observed data.
Cell culture Unless indicated otherwise stated, all cells were cultured in a 5% CO 2 incubator at 37 C. All primary cells and cell-lines were cultured in RPMI 1640 (Sigma-Aldrich) supplemented with kanamycin sulfate, sodium pyruvate, GlutaMAX, non-essential amino-acids and 10% serum (complete medium), and either 10% fetal bovine serum (FBS) for primary cells or 10% bovine calf serum (BCS) for tumor cell-lines with the exception of J558L cells stably expressing NKp44-Fc that were cultured in complete RPMI 1640 medium containing 1% BCS. NK92 and primary mouse and human NK cells were cultured with IL-2 (10 ng/mL). CD3 -
CD19
-NKp44 + CCR6 + tonsilar cells were cultured with human IL-2 (10 ng/mL) and IL-1b (10 ng/mL) for 21 days prior to stimulation. For microarray analysis, CD3 -CD19 -NKp44+CD103+ ILC1 were expanded in IL-2 (10 ng/mL, Peprotech) for 10 days prior to stimulation.
Reporter cell assays NKp44-GFP reporter cells (10 5 ) were mixed 1:1 with target cells or directly stimulated with proteins in 96-well plates for 16h before immunostaining with APC-conjugated anti-NKp44 antibodies and the expression of GFP subsequently analyzed by flow cytometry.
Generation of cytokine-conditioned TC supernatants IL-2 cultured human NK cells were incubated with 250 ng/mL PDGF-DD (R&D Systems) in 24-well plates for 16h in the presence of 1 mg/mL IgG1 (NK DD+IgG sup) or blocking anti-NKp44 3.43.14 mAb (NK DD+a-NKp44 sup). After 16h, TC supernatants were pooled, centrifuged and filtered to remove cellular debris, and then stored at À80 C until further use. B16-pMX and B16-PDGFD stable cell-lines were cultured in 6-well plates for 72h. After 72h, TC supernatants were centrifuged, filtered and then stored at +4 C until further use.
Tumor cell cycle analysis
For analysis of the cell cycle by flow cytometry, Meljuso, cells were cultured in 1:2 NK cell-conditioned TC supernatants (NK DD+IgG sup or NK DD+a-NKp44 sup) or complete RPMI 1640 medium with 10 ng/mL each of human IFN-g and TNF-a (Peprotech) for 48h. Meljuso cells were pulsed with 1 mM BrdU prior to removal from TC plates using trypsin/1 mM EDTA. Single cell suspensions were then washed twice to remove excess BrdU prior to staining with 7-aminoactinomycin D (7-AAD) and APC-conjugated antibodies to BrdU using the Becton Dickinson APC BrdU Flow kit, according to the manufacturer's instructions and then analyzed by flow cytometry. Electronic gates were set according to each stage of the cell cycle and the percentage of events in each gate is indicated.
Tumor growth inhibition assays
Meljuso and Colo38 cancer cell-lines were cultured in complete medium or 1:2 NK cell-conditioned TC supernatants (NK DD+IgG sup or NK DD+a-NKp44 sup) for 48h and 72h, respectively, with or without 2 mg/mL of blocking antibodies to IFN-g and TNF-a in 12-well plates.
Cells were removed using a trypsin/EDTA solution to generate single-cell suspensions and washed twice in complete medium before enumerating the number of live cells by trypan blue exclusion using a hemacytometer (Thermofisher Scientific). A total of 4 3 10 4 cells per well were then cultured in 24-well plates in 1 mL complete RPMI 1640 medium in the absence of cytokines. At the end of each passage, TC supernatants were removed for the detection of inflammatory cytokines and chemokines, and the total number of cells per well enumerated by trypan blue exclusion before re-plating at 4 3 10 4 cells per well in 24-well for the next passage. The number of cells at the end of each passage (as determined by confluence/cell density in control wells) was recorded for a total of 3 passages and the percentage growth relative to control medium determined.
Sorting of ILC subsets Enriched tonsilar CD56
+ cells were stained with PerCP-Cy5.5-conjugated antibodies to CD3 and CD19, PE-conjugated anti-NKp44, and biotin-conjugated antibody to CCR6 followed by APC-conjugated streptavidin, and FITC-conjugated anti-CD103 and sorted on a FACS Aria II (BD Biosciences) into CD3 
NK cell treatments
Unless indicated otherwise, NK cells were stimulated with 250 ng/mL recombinant PDGF-DD (R&D Systems) or 1 mg/mL CUB-TEV-PDGFD or neat B16F10 TC supernatants with or without addition of soluble blocking antibodies (5 mg/mL) for 16h in all assays. For CD107a degranulation assays, CD3 -CD56 + NK cells (500,000 cells) were stimulated in 96-well round bottom plates. FITC-conjugated anti-CD107a antibody was added at the start of the culture. Cells were cultured for 5 hours with 2 mM monensin (Sigma Aldrich) added after the first hour of culture. NK cells were then stained with APC-conjugated mAb to CD56 prior to flow cytometry. For intracellular cytokine staining, NK cells were stimulated in 96-well flat bottom plates. Cells were cultured for 8h with 2 mM monensin added after two hours of culture, before surface staining with PE-conjugated anti-NKp44 and PE-Cy7-conjugated anti-CD56 followed by staining for intracellular cytokines with APC-conjugated antibodies to IFN-g and FITC-conjugated antibodies to TNF-a. For analysis of the upregulation of cell surface NKp44 on mouse NK cells, splenocytes were isolated from NCR2-tg and non-tg mice and, following red blood cell lysis, cultured in 10 ng/mL each of human IL-2 and IL-15 (both Peprotech) for a total of four days with some splenocyte cultures additionally stimulated with 4 ng/mL mouse IL-1b and 10 ng/mL mouse TNF-a (both Peprotech) for 2 days before immunostaining staining with APC-conjugated antibody to NK1.1, FITC-conjugated antibody to mouse CD3 and PE-Cy7-conjugated antibody to NKp44 and DAPI and cell surface NKp44 expression on live (DAPI-) CD3 -NK1.1 + NK cells determined by flow cytometry.
ILC1 and ILC3 treatments
Unless indicated otherwise, ILCs were stimulated with 250 ng/mL PDGF-DD with or without soluble blocking antibodies (5 mg/mL) for 16 h for all assays. For detection of intracellular cytokines in ILC3, enriched CD56 + tonsilar cells were stimulated with 250 ng/mL PDGF-DD for 6h with 2 mM monensin added after the two hours of culture, before either surface staining with APC-conjugated anti-NKp44 and the expression of intracellular cytokines detected with PE-conjugated antibodies to IL-22 and FITC-conjugated antibodies to TNF-a (as in Figure 3A ) or surface staining with PerCP-Cy5.5-conjugated antibodies to CD3 and CD19, APC-conjugated anti-NKp44, PE-Cy7-conjugated anti-CD56, BV421-conjugated anti-CCR6 and BV605-conjugated anti-CD103 and the expression of intracellular cytokine detected with FITC-conjugated antibodies to TNF-a (as in Figure 3B ).
Detection of cancer cell surface ligands for NK cell receptors
Colo38 and Meljuso cells were cultured with 1:2 NK cell-conditioned TC supernatants (NK DD+IgG sup or NK DD+a-NKp44 sup) in 12-well TC plates for 48h before cells were removed using PBS/1 mM EDTA and stained with FITC-conjugated antibodies to CD95/Fas and PE-conjugated antibodies to CD112 and either biotin-conjugated antibodies to CD155/PVR or CRTAM-Fc followed by biotin-conjugated anti-human IgG. Biotin-conjugates were detected with APC-conjugated streptavidin. B16F10 cells were cultured with 10 ng/mL of either murine TNF-a, IFN-g, or TNF-a and IFN-g (both Peprotech) for 48h prior to staining with FITC-conjugated antibodies to CD95/Fas and biotin-conjugated antibodies to CD155 followed by APC-conjugated streptavidin and propidium iodide. Analysis of cellular cytokine secretion IL-2 cultured NK cells or converted tonsil ILC3 (IL-2 and IL-1b) were stimulated in 96-well plates (10 5 cells/well) with or without blocking antibodies and the secretion of IFN-g and TNF-a in the TC supernatants determined using the Th1/Th2/Th17 cytometric bead array (BD Biosciences). In some experiments, IFN-g and TNF-a were induced by cross-linking NKp44 with GaM + a-NKp44 as a surrogate NKp44 ligand. NK cells and ILCs were kept in cytokine-containing medium throughout the assay. PMA/ionomycin was included in some experiments as positive control for cytokine secretion. In tumor cell growth inhibition assays, the secretion of IL-6 and IL-8 by tumor cell-lines at the end of each passage was determined using the Human Inflammatory cytokine CBA (BD Biosciences). The concentration of IL-6 or IL-8 present was normalized relative to the cell number following each passage.
Microarray and data analysis Tonsilar ILC1 cells were sorted from two donors as previously described (Cella et al., 2010; Fuchs et al., 2013) . Briefly, expanded tonsil ILC1 were stimulated with or without 250 ng/mL PDGF-DD for 16h before RNA isolation using the RNeasy Plus Micro Kit (QIAGEN), amplified, and hybridized to the Affymetrix Human Gene (v.1.0) ST arrays. RNA yields from each subset were comparable. Array data were analyzed as previously described (Robinette et al., 2015) . Pathway analysis of microarray data was performed using IPA software (QIAGEN). ) from four different donors were stimulated with 250 ng/mL PDGF-DD or PMA/ionomycin or left unstimulated in 12-well plates for 8 h before RNA isolation. Total RNA was isolated from NK cells and cancer cell-lines using Trizol followed by QIAGEN RNAeasy columns. 500 ng total RNA was used to make Illumina libraries using the TruSeq Stranded Total RNA library prep kit. Libraries were sequenced on an Illumina HiSeq 1000, single-end 50 bp run, to a sequencing depth of between 28 million and 60 million mapped reads per sample. Reads were aligned to a transcriptome file with BWA v0.5.9 (Li and Durbin, 2009) , and the number of reads aligning to each transcript counted with SAMtools (Li et al., 2009 ). These counts were converted to Reads per Million (RPM) by dividing each count by the total number of mapped reads for that sample, and multiplying by 10 6 . Gene expression signatures were derived from RNA-seq data using the RPM values of the transcripts for each NK cell donor ( Figure 2I ). The up-or down-regulation of a transcript in response to PDGF-DD stimulation was determined according to the following criteria. First, a background level of gene expression was established in unstimulated NK cells from the four different donors cultured in IL-2. Transcripts in PDGF-DD-stimulated NK cells with at least eight RPM and at least two-fold expression over unstimulated NK cells were declared to be upregulated in that sample. Similarly, transcripts from PDGF-DD-stimulated NK cells with background expression of at least eight RPM and at most half the expression in unstimulated NK cells were declared to be downregulated. Finally, gene expression was declared to be upregulated upon stimulation with PDGF-DD, if upregulated in at least three of the donor samples, and downregulated, if downregulated in at least two donors. Using gene expression data for each cancer cell-line ( Figure 4I ; MCF, Meljuso, OVCA, or Colo38), the upregulation or downregulation of a gene in response to treatment with TC supernatants from PDGF-DD-stimulated NK cells (NK DD+IgG sup) was determined according to criteria analogous to that used for the stimulation of NK cells with PDGF-DD or PMA/i described above, where the background expression of a transcript was established by taking the geometric mean of its RPM in media or upon stimulation with control TC supernatants from NK cells stimulated with PDGF-DD but with the addition of anti-NKp44 blocking mAbs (NK DD+aNKp44 sup). Pathway analysis of RNA-seq data was performed using IPA software (QIAGEN).
RNA-seq and data analysis
Analysis of TCGA datasets TCGA GBM mRNA gene expression data obtained using the Affymetrix HT Human Genome U133a microarray platform (n = 539 patients) was downloaded through the UCSC data portal (https://xenabrowser.net) and matched to the gene expression data ( Figures  4C and 4D ). 7 of 9 cytokine genes ( Figure 4C ) and 27 of 34 cell cycle genes ( Figure 4D ) were matched with the GBM cohort. Scatterplots were generated plotting a cytokine or cell cycle gene with NCR2. Simple linear regression lines were fitted with correlation between two genes gauged by the Pearson correlation coefficient. The canonical correlation analysis (CCA), a dimension reduction statistical technique, was performed to investigate the overall correlation between a set of genes with NCR2. For CCA, each of the cytokine and cell cycle gene were at centered to have zero mean. A canonical cytokine variate was constructed as the linear combination of the set of centered cytokine genes and a canonical cell cycle variate as the linear combination of the centered cell cycle genes such that the resulting canonical cytokine and cell cycle variate each showed maximized positive correlation with NCR2. The canonical correlation between the constructed canonical cytokine variate with NCR2 and the canonical cell cycle variate with NCR2 were finally reported as a measure of potential absolute magnitude of the overall correlation between NCR2 with the set of cytokine genes and cell cycle genes. The canonical variates are always derived from CCA as being positively correlated with NCR2. The direction of each individual gene's associated linear coefficient, however, indicate the positive or negative correlation direction with the canonical covariate and thus with NCR2.
Tissue immunostaining
For PDGF-D immunostaining of normal and cancer tissues, 4 mM thick sections were deparaffinized with xylene and rehydrated with decreasing concentrations of ethanol. Tissue sections were incubated with rabbit anti-PDGF-D antibody (dilution 1:250) after appropriate antigen retrieval (microwave oven; 2 3 5 minutes at max Watt and 3 3 5 minutes at 750 Watt in EDTA buffer pH 8.0) and revealed by Labeled Polymer-HRP followed by DAB. Immunostained sections were photographed using the DP-70 Olympus digital camera mounted on the Olympus BX60 microscope. For NKp44 immunostaining of GBM, 7 mM frozen sections were dried overnight before fixing in ice cold acetone for 10 mins followed by rehydration in PBS. Slides were blocked in 10% goat serum in PBS before incubating with anti-NKp44 and anti-CD3ε antibodies followed by Alexa 488-conjugated anti-mouse IgG1 and Alexa 568-conjugated anti-mouse IgG2a secondary antibodies supplemented with DAPI. Immunostained sections were imaged on a Zeiss LSM880 Laser Scanning Confocal Microscope. Images were then processed with Zen 2.1 (Zeiss).
Tumor cell injections Adherent B16-pMX or B16-PDGFD stable cells were removed from TC plates using a Trypsin/1 mM EDTA solution and washed twice in PBS before twice passing through a 100 mM cell filter and resuspended in PBS, and 200 mL containing a total of 2 3 10 5 cells injected into the tail vein of either NCR2-tg or non-tg littermate mice, respectively. After 17 days, total surface lung metastases were counted. To establish subcutaneous tumors in mice, 2 3 10 6 cells in 200 mL of PBS were implanted into the rear hind flanks of mice. Tumor growth was monitored by measurement of tumor size with a caliper every other day. Tumor volume was determined by the formula: length x width 2 /2. At the experimental end point, mice were sacrificed, and tumors were removed and processed for flow cytometric analysis.
Measurement of lung tumor area
Formalin-fixed and paraffin embedded mouse lung tissues were sectioned at 3-4 mM and the slides stained with hematoxylin and eosin (H & E) . H & E Slides were digitalized using an Aperio ScanScope CS Slide Scanner (Aperio Technologies) at 40X magnification. Individual tumors were manually selected using Aperio ImageScope (Leica Biosystems Imaging); a software that automatically provides the value of every selected tumor area in mM 2 as output.
Quantitative RT-PCR Total RNA was isolated with TRIzol Reagent (Invitrogen) and single-strand cDNA synthesized using SuperScript III reverse transcriptase kit (Invitrogen). Real-time PCR was performed using SYBR Green real-time PCR master mix (Thermo-Fisher) using a StepOnePlus detection system (Applied Biosystems). Primers were to mouse interferon-g and TNF-a and cyclophilin was used as house-keeping gene.
General Statistical Methods
Data in figures are presented as mean ± SEM. Statistical significance was determined using GraphPad Prism 7.0. Statistical differences were determined by two-tailed Student's t test (between two groups) and a one-way ANOVA among multiple groups and a p-value of % 0.05 was considered significant.
DATA AND SOFTWARE AVAILABILITY
The accession number for the microarray data reported in this paper is GEO: GSE107043. The accession number for the RNA-seq data reported in this paper is GEO: GSE107047. Figure S3 . PDGF-DD Binding to NKp44 Induces TNF-a Secretion by ILC3, Related to Figure 3 Representative dotplots of intracellular TNF-a and IL-22 content and cell surface NKp44 from freshly isolated tonsil ILC3 stimulated with PDGF-DD and/or IL-23. (H) Mean tumor area (mM 2 ) and representative histochemical images of lung metastases from non-tg (n = 7) and NCR2-tg (founder #2; n = 10) mice injected with B16-PDGFD cells. Scale bar, 100 mM. Error bar represents mean ±SEM. *p % 0.05; ****p % 0.0001.
